<span item_type="fundamental" item_id="d6b9b4a0cb66f9664c001f8251c37277" counter_id="ST/US/CODX" env="prod"></span><span item_type="announcement" item_id="648373929448506369" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 145.95 K, missing the estimate of USD 163.5 K.</p><p>EPS: As of FY2026 Q1, the actual value is USD -4.06, missing the estimate of USD -3.75.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -9.215 M.</p><p></p><h4>Revenue</h4><p>Co-Diagnostics, Inc. reported total revenue of $145,954 for the first quarter of 2026, an increase from $50,277 in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span></p><h4>Operating Expenses</h4><p>Total operating expenses were $9,160,597 for the first quarter of 2026, compared to $8,580,643 in the same period last year, driven by research and development spending on clinical studies and to advance other growth initiatives.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span></p><h4>Operating Loss</h4><p>The company experienced an operating loss of -$9,208,411 in the first quarter of 2026, compared to an operating loss of -$8,551,956 in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span></p><h4>Net Loss</h4><p>Net loss for the first quarter of 2026 was -$9,140,038, compared to a net loss of -$7,533,271 in the same period last year, primarily due to higher operating expenses and lower other income, including the absence of certain remeasurement gains recognized in the prior-year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span></p><h4>Adjusted EBITDA Loss</h4><p>Adjusted EBITDA loss was -$8,747,213 for the first quarter of 2026, compared to a loss of -$7,397,727 in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span></p><h4>Cash and Cash Equivalents</h4><p>Cash and cash equivalents totaled $8,230,984 as of March 31, 2026, down from $11,884,607 as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span></p><h4>Operational Highlights</h4><p>Co-Diagnostics, Inc. received a CDSCO license for manufacturing and selling the CoSara PCR Pro® instrument in India and ISO 13485 certification for CoSara’s manufacturing facility in India.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span> The company expanded CoSara Diagnostics’ commercial and distribution territory across South Asia, increasing the regional total addressable market to approximately $13 billion.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span> Shipments of PCRPro instruments and tuberculosis (TB) test materials to India were initiated to support upcoming clinical performance studies.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span> Additionally, an international patent was secured in Japan, and enrollment was completed in upper respiratory Co-Dx test clinical studies with over 1,400 patients.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span> CoMira Diagnostics’ manufacturing facility in Sudair Industrial City in the Kingdom of Saudi Arabia advanced through regulatory approval and lease execution.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span></p><h4>Outlook</h4><p>The company anticipates continued investment in clinical development, regulatory, and commercialization activities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span> Co-Diagnostics, Inc. plans to move towards a 510(k) filing with the FDA for its upper respiratory multiplex test, supported by existing data.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span> Furthermore, preparations are underway to initiate clinical performance studies for its MTB program in India, which is identified as a significant near-term opportunity.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1692415/000149315226023059/ex99-1.htm"></span></p>

Co-Diagnostics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 145.95 K